Filgrastim Biosimilars Market Size, Share & Trends Analysis Report By Application (Febrile Neutropenia, Genital Neutropenia, Idiopathic Neutropenia, and Others), By Distribution Channel (Online Pharmacy, Hospital Pharmacy, and Retail Pharmacy), Region And Segment Forecasts, 2023-2031
Filgrastim Biosimilars Market Size is predicted to expand with a 8.5% CAGR during the forecast period for 2025-2034. Key Industry Insights & Findings from the Report: Governments around the world are promoting the use of biosimilars through various initiatives aimed at enhancing affordability and access. Filgrastim biosimilars have been shown to be effective and safe for managing neutropenia in cancer patients, which enhances their ado...
Report ID: 1076 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 175
Veterinary Antibiotics Market Size, Share & Trends Analysis Report By Product Type (Tetracyclines, Penicillins, Sulfonamides, Macrolides, Aminoglycosides, Lincosamides, Fluoroquinolones, Other Antimicrobials and Antibiotics, By Mode Of Delivery, By Animal Type, Region And Segment Forecasts, 2025-2034
Veterinary Antibiotics Market Size is valued at USD 4.99 Billion in 2024 and is predicted to reach USD 6.95 Billion by the year 2034 at a 3.5 % CAGR during the forecast period for 2025-2034. Key Industry Insights & Findings from the Report: The market is in great demand due to the increasing number of pet diseases worldwide, which leads to market growth. The need for efficient veterinary antibiotic treatments is driven by the rising in...
Report ID: 1128 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
Cancer Biosimilars Market Size, Share & Trends Analysis Report By Type (Lung Cancer, Breast cancer, Ovarian cancer, Prostate cancer, Lymphoma, Others), By Distribution Channel, By Drug Class, By Route of Administration, Region And Segment Forecasts, 2023-2031
The Cancer Biosimilars Market is expected to grow at a 20.0 % CAGR during the forecast period for 2023-2031. Biosimilar is defined as a type of biological product that is approved by respective regulatory bodies because of its clinical similarity to already approved biological products. This is relatively cheaper than biologics. The abnormal growth of call is called cancer. Cancer is the second leading cause of death across the globe. Ma...
Report ID: 1078 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
Etanercept Biosimilar Market Size, Share & Trends Analysis Report By Applications (Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, And Ankylosing Spondylitis), Distribution Channel, Region And Segment Forecasts, 2025-2034.
The Etanercept Biosimilar Market Size is valued at XX Million in 2024 and is predicted to reach XX Million by the year 2034 at an 17.8% CAGR during the forecast period for 2025-2034. Etanercept is a tumor necrosis factor alpha (TNF-α) inhibitor, an important inflammatory disease mediator in various articular diseases. Etanercept was the first tumour necrosis factor-alpha (TNF-α) inhibitor approved for the treatment of rhe...
Report ID: 1068 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
Rituximab Biosimilar Market Size, Share & Trends Analysis Report By Brand, By Application, By Route of Administration, By Molecule Type, By Distribution Channel Region And Segment Forecasts, 2025-2034
Rituximab Biosimilar Market is expected to grow at a 12.3% CAGR during the forecast period for 2025-2034. Rituximab is a chimeric anti-CD20 antibody that binds to the CD20 antigen present on the standard and malignant B cells surface. It is indicated for the treatment of blood cancer (CD20-positive) such as chronic lymphocytic leukemia and non-Hodgkin’s lymphoma, as well as an autoimmune disorder such as Rheumatoid arthritis. Rituximab i...
Report ID: 1081 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
Synthetic Lethality-based Drugs and Targets Market Size, Share & Trends Analysis Report By Type (Monotherapy, Combination Therapy), By Application (Medical Research Institution, Hospital and Clinic), By Region, And By Segment Forecasts, 2025-2034
Synthetic Lethality-based Drugs and Targets Market Size is predicted to witness a 14.5% CAGR during the forecast period for 2025-2034. Synthetic lethality refers to a genetic and cancer treatment notion in which the simultaneous dysfunction of two genes results in cell death, whereas the dysfunction of either gene alone does not have the same effect. This method is employed to create precise cancer treatments that take advantage of parti...
Report ID: 2657 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
Vitamins, Minerals and Supplements CDMO Market Size, Share & Trends Analysis Distribution by Types (Vitamins, Minerals, Dietary Supplements), Dosage Form (Tablets & Capsules, Powder, Softgel), Service Type (Product Formulation and Development, Manufacturing and Packaging, Research & Development (R&D), Regulatory Compliance), Company Size- and Segment Forecasts, 2025-2034
Vitamins, Minerals and Supplements CDMO Market Size is valued at USD 41.74 Bn in 2024 and is predicted to reach USD 97.60 Bn by the year 2034 at an 9.0% CAGR during the forecast period for 2025-2034. The Vitamins, Minerals, and Supplements (VMS) Contract Development and Manufacturing Organization (CDMO) market is a rapidly growing segment within the broader nutraceutical industry. VMS CDMOs provide comprehensive services for the development, m...
Report ID: 2669 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 165
Lentiviral Vector (LVV) CDMO Services Market Size, Share & Trends Analysis Report By Service Type (Process Development & Analytical Services, GMP Manufacturing of LVV, Non-GMP / Preclinical LVV Production, Fill–Finish & Packaging Services, Quality, Regulatory & Tech Transfer Services, Integrated End-to-End LVV CDMO Services), By Scale / Manufacturing Stage (Preclinical / Research-Scale Manufacturing, Early Clinical Manufacturing (Phase I / II), Late-Clinical & Commercial-Scale Manufacturing (Phase III / Commercial)), By Application, By End User, By Region, and By Segments Forecast, 2025-2034
Global Lentiviral Vector (LVV) CDMO Services Market Size is predicted to record a 9.0% CAGR during the forecast period for 2025-2034. Lentiviral vectors (LVs) CDMO Services are helpful for gene transfer in mammalian cells because they can efficiently transmit genes from one cell type to another. Lentivirus infections can incubate for a long time and persist for years in animals and humans. The onset of symptoms and initial infection could happen...
Report ID: 2374 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
Next Generation Drug Conjugates Market Size, Share & Trends Analysis Report, By Type (Peptide Receptor Radionuclide Therapy, Ligand mediated RNAi Conjugate, Ligand Conjugated Anti Sense Medicine and Peptide Drug Conjugate), By Type of Targeting Ligand (Amino Sugar, Peptide, Lipid, Small Molecule and Virus-like Particles), By Type of Payload (Peptide, Small Molecule, Oligonucleotide, Radionuclide), By Type of Therapy (Monotherapy, Combination Therapy), By Route of Administration, By Target Indications, By Region, Forecasts, 2025-2034
Global Next Generation Drug Conjugates Market Size was valued at USD 2.9 Bn in 2024 and is predicted to reach USD 12.1 Bn by 2034 at a 15.2% CAGR during the forecast period for 2025-2034. The next-generation drug conjugates (NGDCs) market represents a paradigm shift in cancer therapy, leveraging the synergistic potential of targeted drug delivery and enhanced therapeutic efficacy. NGDCs are a class of bioconjugates that combine cytotoxic payload...
Report ID: 2482 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
Lipid Nanoparticle Raw Materials Market Size, Share & Trends Analysis Report, By Application (Therapeutics and Research), By Product (Kits, Reagents, Others), By Disease Indication (Cancer, Infectious Diseases, Blood Diseases, Others), By End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Others), By Region, Forecasts, 2025-2034
Global Lipid Nanoparticle Raw Materials Market Size was valued at USD 239.4 Mn in 2024 and is predicted to reach USD 421.2 Mn by the year 2034 at a 6.0% CAGR during the forecast period for 2025-2034. Lipids, stabilizers, and occasionally targeting ligands make up the different raw elements that make up lipid nanoparticles. Phospholipids, such as phosphatidylcholine and cholesterol, are often utilized lipids. Several important reasons are dr...
Report ID: 2367 |
Delivery: Immediate |
Published: June 2025 |
No. of Pages: 180
Pharmaceuticals